Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish Heart Failure Registry
21 May 2022 (00:00 - 00:00)
Organised by:
About the speaker
University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)
4 More presentations in this session
Doctor A. D'Amato (Rome, IT)
Impact of obstructive sleep apnea in patients undergoing left ventricular assist device implantation
Doctor N. Patel (Hartford, US)
Mr M. Garus (Wroclaw, PL)
Access the full session
The Event
Heart Failure 2022
21 May - 24 May 2022
You may be interested in
Congress Presentation
Congress Presentation
